Atherosclerosis clinical trials at UCLA
8 in progress, 6 open to eligible people
Comparing Perclose to Statseal in Conjunction With Perclose in Femoral 6 French Arteriotomy Closure
open to eligible people ages 18 years and up
The purpose of this clinical study is to compare how well two different devices for achieving hemostasis perform in patients undergoing transfemoral procedures with 6 French Access. Both devices are approved by the FDA for this use, and have already been used by clinicians on patients undergoing transfemoral procedures. It is believed that the use of both devices in combination compared to the Perclose alone will shorten the time that it takes to 'seal' the artery, resulting in a shorter period of time that patients would need to lay flat.
Los Angeles, California and other locations
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
open to eligible people ages 18-85
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Santa Monica, California and other locations
Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
open to eligible people ages 40 years and up
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Los Angeles, California and other locations
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
open to eligible people ages 30 years and up
An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.
Los Angeles, California
Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
open to eligible people ages 18 years and up
The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.
Torrance, California and other locations
Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
open to eligible people ages 18 years and up
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.
West Los Angeles, California and other locations
Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Sorry, not yet accepting patients
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
Torrance, California
Diet-induced Elevations in LDL-C and Progression of Atherosclerosis
Sorry, in progress, not accepting new patients
This is an observational study examining the progression of subclinical coronary atherosclerosis in healthy participants who have an elevated LDL-C (above 190mg/dl) secondary to diet not associated with genetic familial hypercholesterolemia (FH). This study participants are classified to be Lean-Mass-Hyper-Responder (LMHR).
Torrance, California
Our lead scientists for Atherosclerosis research studies include David Liebeskind, MD Rushi V. Parikh Matthew A Budoff, MD.
Last updated: